Risk prediction in early triple negative breast cancer
BMJ 2024; 387 doi: https://doi.org/10.1136/bmj.q2088 (Published 23 October 2024) Cite this as: BMJ 2024;387:q2088Linked Research
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature
- Sofia Mason, medical oncologist and doctoral candidate1 2
- 1Chris O’Brien Lifehouse, Sydney, NSW, Australia
- 2Garvan Institute of Medical Research, St Vincent’s Healthcare Clinical Campus UNSW Sydney, Sydney, NSW, Australia
- sofia.mason{at}unsw.edu.au
Triple negative breast cancer is an aggressive subtype of breast cancer characterised by a lack of oestrogen, progesterone, and HER2 receptors which, if present, would guide the use of targeted therapies. This disease lacks validated prospective biomarkers predicting response to treatment and outcomes beyond basic staging information. The traditional mainstay of systemic treatment for triple negative breast cancer has been chemotherapy.
We need to develop methods to guide treatment decisions in an increasingly complex therapeutic landscape in operable triple negative breast cancer. Enhanced understanding of risk of recurrence and sensitivity to treatment, as is the aim of the linked randomised trial by He and colleagues (BCTOP-T-A01) (doi:10.1136/bmj-2024-079603),1 can inform decisions about who needs intensive treatment and who might be spared therapies with serious and often permanent toxicities.
The BCTOP-T-A01 trial is the first to prospectively validate a multigene tumour RNA signature to guide choice of chemotherapy in patients with early triple negative breast cancer.1 This …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.